COVID-19 during Early Phase of Autologous Stem Cell Transplantation.
Sławomir MilczarekBartłomiej BaumertAnna SobuśEwa Wilk-MilczarekKrzysztof SommerfeldBogumiła OsękowskaEwa BorowieckaEdyta PaczkowskaAleksandra ŁanochaWojciech PoncyliuszKonrad JaroszBogusław MachalińskiPublished in: Medicina (Kaunas, Lithuania) (2021)
We present one of few cases of COVID-19 occurrence during the early phase of autologous hematopoietic stem cell transplantation. We observed an interesting correlation between the patient's rapid clinical deterioration and myeloid reconstitution that cannot be assigned to engraftment syndrome. Our report emphasizes the need to investigate whether timely steroid therapy upon neutrophil engraftment in the setting of COVID-19 could limit the extent of lung injury and prevent ARDS. Furthermore, we discuss a significant issue of possible prolonged incubation of the virus in heavily pretreated hematological patients.
Keyphrases
- coronavirus disease
- stem cell transplantation
- sars cov
- bone marrow
- end stage renal disease
- high dose
- acute myeloid leukemia
- ejection fraction
- cell therapy
- newly diagnosed
- chronic kidney disease
- risk assessment
- respiratory syndrome coronavirus
- prognostic factors
- peritoneal dialysis
- acute respiratory distress syndrome
- platelet rich plasma
- hematopoietic stem cell
- extracorporeal membrane oxygenation
- intensive care unit
- immune response
- patient reported